This study aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expression and the mechanism by which EphA2 is involved in the epithelial-mensenchymal transition (EMT) of gastric cancer cells. EphA2 expression levels were upregulated and positively correlated with metastasis and EMT markers in human gastric cancer specimens. Modulation of EphA2 expression levels had distinct effects on cell proliferation, cell cycle, migration, invasion and morphology in the gastric cancer cell lines SGC7901 and AGS in vitro and in vivo. Overexpression of EphA2 resulted in the upregulation of the EMT molecular markers N-cadherin and Snail, as well as the Wnt/b-catenin targets TCF4, Cyclin-D1 and c-Myc, while silencing EphA2 using short hairpin RNA had the opposite effect. Furthermore, inhibition of the Wnt/b-catenin pathway by XAV939 negated the effect of EphA2 overexpression, whereas activation of the Wnt/b-catenin pathway by LiCl impaired the effect of the EphA2 knockdown on EMT. These observations demonstrate that EphA2 upregulation is a common event in gastric cancer specimens that is closely correlated with cancer metastasis and that EphA2 promotes EMT of gastric cancer cells through activation of Wnt/b-catenin signaling.
INTRODUCTION
Receptor tyrosine kinases (RTKs), a large family of transmembrane receptors involved in coordination of diverse cellular functions including proliferation, differentiation and apoptosis, are frequently found mutated or overexpressed in human cancer and are encoded by the largest known group of oncogenes with shared structural homology.
1 Consisting of 14 distinct receptors, the erythropoietin-producing hepatocellular (Eph) receptors form the biggest subfamily of RTKs. The Eph family member EphA2 is usually expressed at a low level in normal epithelial cells. 2 In contrast, overexpression of EphA2 has been widely detected in numerous solid tumors, including glioma, non-small-cell lung cancer, gastric cancer, hepatocellular carcinoma, colorectal and endometrial cancers. [3] [4] [5] [6] [7] [8] EphA2 overexpression in tumors correlated with metastasis and poor prognosis. Growing evidence indicates the importance of EphA2 overexpression in cell transformation, primary tumor initiation, tumor progression, angiogenesis and metastasis in a variety of cancer models. 9, 10 We have previously demonstrated that silencing of EphA2 could inhibit gastric cancer SGC-7901 cell proliferation, invasion and matrix metalloproteinase-9 expression in vitro and in vivo. 11 Moreover, EphA2 overexpression was found to be able to promote ovarian cancer growth by enhancing cell-extracellular matrix adhesion and increasing anchorage-independent growth. 12 Further research efforts are needed to clarify the exact mechanisms of EphA2 in gastric cancer invasion-metastasis.
Epithelial-mesenchymal transition (EMT) is a physiological process in which epithelial cells acquire the motile and invasive characteristics of mesenchymal cells. 13 EMT is an important event in the tumor invasion-metastasis cascade whereby epithelial cell layers lose polarity along with cell-cell adhesion and then undergo a dramatic remodeling of the cytoskeleton. 14 EMT is induced by genetic and epigenetic changes within the transforming cells, as well as signals from the tumor microenvironment. 15 A variety of signaling pathways are involved in EMT, including the tumor growth factor-b, nuclear factor-kB, Notch, RTK/Ras and Wnt/b-catenin pathways. 16 The Wnt/b-catenin pathway is involved in the maintenance of stem cell properties, as well as serving as an important regulator of EMT in cancer cells. 17 Importantly, the RTK/Ras/MAPK pathway cooperates with the Wnt/b-catenin pathway to control cell fates, possibly by convergent upregulation of common targets such as Hox genes. 18 EphA2 receptor is a component of RTK/Ras signaling, and is negatively correlated with E-cadherin levels in human gastric cancer. 19 However, it is unknown through which pathway EphA2 promotes EMT.
In this study, we determined that EphA2 overexpression induced gastric cancer cell lines (AGS and SGC7901) to undergo EMT and promoted cell migration and invasion through the Wnt/b-catenin pathway. The role of EphA2 in the regulation of EMT through the Wnt/b-catenin pathway provides a potential drug target for the treatment of gastric cancer and the prevention of gastric cancer metastasis. immunohistochemistry analysis. EphA2 showed significantly higher expression in gastric cancer tissues relative to adjacent normal gastric mucosa (Figure 1 ). We then assayed the expression levels of EMT-related proteins, such as Snail, N-cadherin, E-cadherin and b-catenin in 251 gastric cancer specimens by immunohistochemistry and evaluated the correlations between the expression levels of EMT-related proteins and EphA2. As shown in Table 1 , the expression levels of EphA2, Snail, N-cadherin and b-catenin in gastric cancer tissues were significantly higher than those in adjacent normal gastric mucosas (Po0.05); E-cadherin, by contrast, showed reduced expression levels in gastric cancer tissues with respect to adjacent normal mucosa (Po0.05). The correlations between the clinicopathologic features of gastric cancer patients and expression levels of EphA2, Snail, N-cadherin, E-cadherin and b-catenin are summarized in Table 2 . There were close correlations between the levels of EphA2, Snail, N-cadherin, E-cadherin and b-catenin and depth of tumor invasion. Especially notable, the nuclear expression levels of b-catenin were increased in gastric cancer tissues compared with adjacent normal mucosa, and were also related to the depth of tumor invasion ( Table 2 ). E-cadherin, Snail and E-cadherin had significant correlations with patients' tumor metastasis status (Po0.05). Table 3 shows that the expression levels of EphA2 were positively correlated with that of Snail, N-cadherin and b-catenin in gastric cancer tissues, but inversely correlated with E-cadherin expression. 
Age (years) o60 Figure 1) . The results suggest that EphA2 is a driving force of EMT in gastric cancer cells.
EphA2 modulates cell cycle, proliferation, migration and invasion in gastric cancer cells We established stable gastric cancer cell lines (SGC-790-1 and AGS) in which EphA2 was either inhibited through shRNA expression or induced by EphA2 expression vectors. These cell lines were used to determine whether EphA2 could affect the cell cycle, proliferation, migration and invasion properties of gastric cancer cells. Figure 2 confirmed that both mRNA and protein levels of EphA2 were upregulated in EphA2 overexpression cell lines (designated as 'EphA2'), while downregulated in EphA2-silencing cells ('EphA2 Si').
Cell proliferation was determined at 24, 48, 72 and 96 h after seeding using an MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. As shown in Figure 3 , the proliferation of SGC-7901 and AGS cells was significantly increased upon EphA2 overexpression and decreased after silencing of endogenous EphA2 at each time point (Figure 3a) . The proliferation curves indicate that EphA2 might enhance the proliferation rate of gastric cancer cells.
Cell cycle phase distribution was determined by flow cytometry analysis. Figure 3b shows that EphA2 overexpression resulted in a substantial reduction in the G0-G1 phase and an increase in the number of cells in the S phase at 48 h after seeding. Little effect was noticed for the G2-M phase of the cell cycle. EphA2 silencing had the opposite effect, increasing the number of cells in the G0-G1 phase and reducing the number of cells in the S phase at 48 h after seeding. These results suggest that EphA2 accelerates gastric cancer cell cycle progression in vitro.
To demonstrate the effect of EphA2 on the migration and mobility of gastric cancer cells, an in vitro cell invasion assay was performed based on the principle of the Boyden chamber assay. Cells that migrated through the Matrigel matrix are presented in Figure 3c . When endogenous EphA2 was inhibited, the number of cancer cells migrating through the Matrigel decreased significantly compared with the control group, while EphA2 overexpression had the opposite effect (Po0.05). To provide further support for the positive effect of EphA2 expression on cell migration ability, the in vitro scratch wound-healing assay was used. As shown in Figure 3d , in the EphA2-silenced group gastric cancer cells migrated significantly slower when compared with the control group. Under the same conditions, overexpression of EphA2 accelerated cell migration through the scratch wound (Po0.05). These results imply that EphA2 facilitates gastric cancer cell migration and invasion.
EphA2 promotes gastric cancer cell proliferation and metastasis in vivo We next tested whether EphA2 could have a role in tumorigenesis in vivo by using a nude mouse xenograft model. Nude mice transplanted with SGC-7901 cells developed solid tumors in 30 days. Tumor volume and weight were increased when EphA2 was stably overexpressed in SGC-7901 cells ('EphA2') when compared with the control group ('blank'), whereas the tumor volume and weight were decreased in the EphA2-silencing group ('EphA2 Si') when compared with the 'blank' group (Figures 4a-c) . We performed immunohistochemistry assays of EphA2, Snail, N-cadherin, E-cadherin and b-catenin proteins on mouse tumor sections, and found that EphA2, Snail, N-cadherin and b-catenin were upregulated in 'EphA2' tumors, while E-cadherin was downregulated. 'EphA2 Si' group tumors had downregulated EphA2, Snail, N-cadherin and b-catenin and upregulated E-cadherin (Supplementary Figure 2) . We also explored whether EphA2 could promote gastric cancer cell metastasis in vivo. SGC-7901 cells ('blank', 'EphA2' and 'EphA2 Si') were injected into the tail vein of nude mice and the number of lung metastatic foci were evaluated 30 days later. A significantly higher number of lung metastasis nodules could be observed for EphA2-overexpressing cells compared with control cells, while EphA2-silencing reduced the number of nodules observed (Figures 4d and e) .
EphA2 regulates the Wnt/b-catenin pathway in gastric cancer cells The Wnt/b-catenin signaling pathway is implicated in numerous aspects of development, cell biology and physiology including the EMT process. We performed quantitative polymerase chain reaction and western blotting to measure whether EphA2 regulated the Wnt/b-catenin pathway in gastric cancer cells (SGC-7901 and AGS) by testing its downstream targets such as TCF-4, Cyclin-D1 and c-Myc. As shown in Figure 5 , overexpression Abbreviation: Eph, erythropoietin-producing hepatocellular.
EphA2 promotes EMT in gastric cancer J Huang et al of EphA2 significantly increased the mRNA and protein levels of TCF-4, Cyclin-D1 and c-Myc, while EphA2-silencing significantly reduced the mRNA and protein levels of these targets. These results suggested that EphA2 might be involved in activating the Wnt/b-catenin pathway in gastric cancer cells.
EphA2 promotes EMT in gastric cancer through the Wnt/b-catenin pathway In the previous experiments, we found that b-catenin showed higher expression in gastric cancer tissues with respect to adjacent normal mucosas and that nuclear expression of b-catenin was related to the depth of tumor invasion. To further explore whether EphA2 promotes EMT through the Wnt/b-catenin pathway, we used either the Wnt/b-catenin signaling-specific inhibitor XAV939 or Wnt/b-catenin activator LiCl to control the Wnt/b-catenin signaling in gastric cancer cell lines (SGC-7901 and AGS). We observed that XAV939 downregulates Wnt/b-catenin signaling targets TCF-4, Cyclin-D1 and c-Myc, while LiCl upregulates them ( Figure 6a ). We also observed that XAV939 upregulates EphA2 expression, while LiCl downregulates it (Figure 6a ), but the exact mechanism is still unknown. One of the mechanisms by which XAV939 inhibits the Wnt/b-catenin signaling is by facilitating the degradation of b-catenin protein by stabilizing the APC/Axin/glycogen synthase kinase (GSK)-3b complex, which depends on decreasing the phosphorylation levels of GSK-3b (Ser9 site). Alteration of p-GSK3b
Ser9 could reflect altered Wnt/b-catenin signaling activities and the upregulation of p-GSK-3b
Ser9 that is a marker for hyperactivation of this signaling. Figure 6a shows that p-GSK-3b
Ser9 levels are decreased by XAV939, but increased by LiCl. EphA2 overexpression increased p-GSK-3b
Ser9 levels, while EphA2-silencing had the opposite effect. We also observed that XAV939 could interfere with EphA2's promotion of p-GSK-3b Ser9 , and LiCl could rescue p-GSK-3b
Ser9 after EphA2-silencing (Figure 6a ). The levels of the EMT markers N-cadherin, Snail and b-catenin were increased in EphA2 overexpression cells, while E-cadherin was decreased. Inhibition of Wnt/b-catenin signaling by XAV939 neutralized the effect of EphA2 overexpression; while LiCl opposed the effect of EphA2-silencing (Figure 6a) . 
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We further assayed the effects of XAV939 or LiCl on gastric cancer cell migration and invasion. Figures 6b and c show that cell migration and invasion were increased in EphA2 overexpression cells, while XAV939 can impair these effects. Silencing of EphA2 decreased cell migration and invasion but LiCl can block this outcome. The above results suggest that EphA2 promotes EMT in gastric cancer cells through the Wnt/b-catenin pathway.
DISCUSSION
In epithelial carcinomas, EMT endows tumor cells with the ability to leave the primary tumor and invade the local tissue and blood vessels, setting the stage for metastatic spread. 7 Loss of epithelial-cell markers (for example, E-cadherin) and gain of mesenchymal-cell markers (for example, N-cadherin and Snail), particularly at the leading edge or invasive front of solid tumors, have been reported in human tumor specimens. These genetic changes are associated with tumor progression to metastasis and are accompanied by the activation of signaling networks associated with the migration and survival of mesenchymal cells in an anchorage-independent environment. 14 Recently, it has been suggested that EphA2 may function as an activator of EMT in carcinogenesis and that this could be a mechanism of EphA2-mediated cancer invasion and metastasis. 
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This is supported by the observation that EphA2-overexpressing cells display a mesenchymal-like phenotype (E-cadherin-negative and N-cadherin-positive). 20 Taddei et al. 21 showed that, due to their amoeboid mobility style, EphA2-overexpressing prostate carcinoma cells gained an invasive capability and the ability to escape from primary tumors and form bone-targeted metastases. This study demonstrates that EphA2 promotes the cell cycle, proliferation, migration and invasion in gastric cancer cells (both AGS and SGC7901). EphA2 overexpression accelerated these proliferative and metastatic properties of gastric cancer cells and suppression of EphA2 had the opposite effect. We also observed that EphA2 expression significantly correlated with the EMT markers and metastasis status of gastric cancer patients. Western blotting and immunofluorescence analyses show that EphA2 upregulated the expression of Snail, N-cadherin, b-catenin and downregulated E-cadherin in gastric cancer cells. This is evidence that EphA2 can promote EMT in gastric cancer cells. More importantly, we observed that EphA2 could promote gastric cancer proliferation and metastasis in vivo by using a nude mouse xenograft model. In xenograft mouse tumor sections, the EphA2-overexpressing tumors showed higher expression of EMT markers (Snail, N-cadherin and b-catenin) and lower expression of E-cadherin compared with the control group. This suggests that EphA2 promotes EMT in vivo.
EphA2, as a member of the RTK family, transduces extracellular signals into the cell to modulate downstream signaling networks such as the Ras and phosphatidylinositol 3 0 -kinase signaling pathways. [22] [23] [24] EphA2-Ephrin-A1 signaling is complex and celltype-dependent, making the goal of defining the exact role of EphA2-Ephrin-A1 in neoplasia a challenge. In addition, EphA2 is reported to be a direct transcriptional target of Raf-MARK pathways. 25, 26 The complexity of the EphA2 signaling had been precisely investigated in a study of Miao et al. 24 The study demonstrated that EphA2 kinase has two opposing roles in the regulation of chemotactic cell migration: ligand-independent promotion and ligand-dependent inhibition via a reciprocal regulatory loop with Akt. Because of the complexity of EMT induction in the tumor microenvironment, EMT involves several related signaling pathways, such as tumor growth factor-b, nuclear factor-kB, Notch and Wnt/b-catenin. 16 Wnt/b-catenin signaling has a major impact on EMT during cancer progression. Translocation of b-caternin into the nucleus may result in the loss of E-cadherin and subsequent induction of EMT. Inhibition of Wnt/b-catenin signaling can block EMT transcription factors and promote epithelial differentiation. In the absence of Wnt signals, cytosolic b-catenin is targeted for proteasomal breakdown by the APC/Axin/GSK complex. When the Wnt/b-catenin pathway is activated, binding of Wnt molecules to frizzled receptors inhibits the activity of the destruction complex and allows b-catenin to accumulate and to translocate to the nucleus. 27, 28 After translocation to the nucleus and binding to TCF, b-catenin promotes transcriptional activation of specific target oncogenes associated with cell proliferation, such as Cyclin-D1 or c-Myc. [29] [30] [31] However, the mechanism underlying EphA2 overexpression induced EMT in human gastric cancer remains unclear. In this study, we observe that EphA2 overexpression can facilitate EMT and activate the Wnt/b-catenin pathway. This was confirmed by the observation of the upregulation of p-GSK-3b
Ser9 , b-catenin, TCF-4, Cyclin-D1 and c-Myc. We further demonstrated that expression changes in EMT markers (E-cadherin, N-cadherin, Snail) induced by EphA2 overexpression or silencing can be reversed by XAV939 or LiCl, respectively. The results revealed that EphA2 potentially promotes EMT via Wnt/b-catenin signaling in gastric cancer cells. EphA2 can also activate RTK/Ras signaling; therefore, there is a possible cross-talk between Ras and Wnt signaling in regard to the role of EphA2 in EMT.
In summary, this study reports that EphA2 functions as an EMT promoter by enhancing the Wnt/b-catenin pathway and hence has an important role in cancer invasion and metastasis. EphA2 is selectively overexpressed in several cancers, especially in gastric cancer, while expressed at comparatively reduced levels in normal cells. EphA2 is therefore an excellent candidate for the development of a targeted gastric cancer therapy that will block 
MATERIALS AND METHODS Materials
Anti-EphA2, Snail, b-catenin, E-cadherin, N-cadherin, TCF-4, Cyclin-D1, phospho-ERK, glyceraldehyde 3-phosphate dehydrogenase and c-Myc antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-p-GSK-3b Ser9 antibody was obtained from Cell Signaling Technology (Beverly, MA, USA). Dimethyl sulfoxide, XAV939 and LiCl were purchased from Sigma-Aldrich (St Louis, MO, USA).
Cell culture
The human gastric adenocarcinoma cell lines SGC-7901 and AGS were obtained from the Xiangya Central Experiment Laboratory, Central South University (Changsha, China). The cells were cultured in PRMI 1640 
Plasmid construction and transfection
EphA2 coding sequence and EphA2 shRNA using a recombinant adenovirus gene delivery system were constructed by GeneChem Biomedical Co. Ltd (Shanghai, China). A blank vector adenovirus gene delivery system was used as a negative control. A total of 5 Â 10 5 SGC-7901 or AGS cells were seeded into each well of a 6-well plate. When the cells reached 80-90% confluence on the day of transfection, the overexpression of EphA2 or a blank vector recombinant adenovirus gene delivery system was transfected into the cells. Five groups of cells were used in this study including untransfected cells ('blank'), cells transfected with empty GFP vector ('GFP'), cells transfected with EphA2 expression vector ('EphA2'), cells transfected with EphA2-shRNA vector ('EphA2 Si') and cells transfected with scrambled shRNA vector ('Si Ctrl'). In the latter part of the study, 'GFP' and 'EphA2' cells were treated with either 10 mmol/l XAV939 (a Wnt/b-catenin signaling inhibitor) or dimethyl sulfoxide for 24 h; 'Si Ctrl' and 'EphA2 Si' cells were treated with 20 mmol/l LiCl (a Wnt/b-catenin signaling activator) or dimethyl sulfoxide for 24 h to assay the influence of Wnt/b-catenin signaling on the function of EphA2.
Patient selection and tissue preparation
Between January 2010 and December 2011, 251 patients with gastric adenocarcinoma including 149 male and 102 female subjects, aged between 34 and 78 years (59.8 ± 12.1 years) in the Department of General Surgery of Xiangya Hospital of Central South University (Changsha, China) were selected (see Table 2 for patients' clinicopathologic features). Radical resection was performed on these patients. The patients received neither chemotherapy nor radiotherapy before surgery. The study was approved by the Research Ethics Committee of Xiangya Hospital, Central South University. Cancer tissues were excised and fixed in 10% neutral-buffered formalin, and then embedded in paraffin blocks.
Immunohistochemistry
The paraffin-embedded sections were cut at 4 mm thick and then deparaffinized and rehydrated. Immunohistochemical staining was performed to detect the expression of EphA2, Snail, E-cadherin, N-cadherin and b-catenin by using the DAKO EnVision System (Dako, Glostrup, Denmark). After proteolytic digestion, the slides were blocked for peroxidase with 2.5% hydrogen peroxide in methanol for 30 min at room temperature, and then incubated with primary antibody overnight at 4 1C. After washing, the slices were incubated with peroxidase-labeled polymer and substrate chromogen. Finally, sections were incubated in phosphatebuffered solution containing diaminobenzidine for 5 min at room temperature. The staining results of targeted proteins were observed under the microscope. Negative controls were prepared by substituting primary antibody with non-immune rabbit serum. Two independent pathologists evaluated and scored the sections in 10 random visual fields for each section (double-blinded). The evaluation of staining result was graded semiquantitatively as described previously, 8 the expression intensity scores (0 point ¼ 0-5%; 1 point ¼ 6-25%; 2 points ¼ 26-50%; 3 points ¼ more than 50%) and positive staining cell scores (1 point ¼ weak intensity; 2 points ¼ moderate intensity; 3 points ¼ strong intensity) were summed. The sum scores X3 points were considered as significant overexpression and noted as positive to simplify data analysis.
MTT assay
Cells were incubated in 96-well plates at a density of 1 Â 10 4 cells per well for 24 h. Then, after different time points, 10 ml of MTT dye (5 mg/ml; Sigma-Aldrich) was added and incubated for another 4 h at 37 1C. Then, 150 ml of dimethyl sulfoxide was added to each well and mixed for 10 min. Spectrometric absorbance at a wavelength of 490 nm was determined with a microplate reader (Bio-Rad, Hercules, CA, USA). Each sample had three replicates.
Cell cycle analysis
Cells were harvested 48 h after seeding and single-cell suspensions containing 1 Â 10 6 cells were fixed with 75% alcohol. The cell cycle was monitored using propidium iodide staining of the nuclei. The fluorescence of DNA-bound propidium iodide in the cells was measured with a FACScan flow cytometer (BD Biosciences, San Diego, CA, USA).
Scratch wound-healing assay Cells were plated and grown overnight to confluence in a 6-well plate. Monolayers of cells were wounded by dragging a pipette tip. Cells were washed to remove cellular debris and allowed to migrate for 24 h. Images were taken at 0 and 24 h after wounding under the inverted microscope.
Cell invasion assay
Transwell invasion assays were performed in 24-well 8-mm pore size transwell plates according to the manufacturer's instructions (Corning, New York, NY, USA). The bottom of transwell chamber was coated with BD Matrigel Basement Membrane Matrix (BD Biosciences, San Diego, CA, USA). The upper chamber was filled with 1 Â 10 5 cells in RPMI 1640 containing 5% fetal bovine serum. The lower chamber was filled with RPMI 1640 containing 25% fetal bovine serum as a chemoattractant. After the chambers were incubated for 24 or 48 h at 37 1C, non-invading cells on the upper side of the chamber were removed from the surface of the membrane by scrubbing, and invading cells on the lower surface of the membrane were fixed with methanol, mounted and dried. The number of cells invading through the matrigel was counted by a technician blinded to the experimental settings in four randomly selected microscopic fields of each filter. The test repeated three times.
Real-time reverse transcriptase-PCR Total RNA was extracted using the Trizol (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The cDNA was synthesized using 1 mg of total RNA and TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). The primers for real-time PCR were listed as Supplementary Table 1. The relative levels of target genes' mRNA were expressed as the ratio of target to b-actin and calculated from the standard curve as directed. All reported results are the average ratios of three different independent experiments.
Western blotting
Whole-cell extracts were prepared using 0.14 M NaCl, 0.2 M triethanolamine, 0.2% sodium deoxycholate, 0.5% Nonidet P-40 and supplemented with a protease inhibitor (Sigma-Aldrich). Fifty micrograms of proteins was loaded onto each well. The transferred membranes were subsequently incubated overnight at 4 1C with primary antibody and then secondary antibody for 1 h. Bands were visualized and quantitated by using the ECL Advance Detection System (Amersham Biosciences, Piscataway, NJ, USA).
Immunofluorescence
Cells were grown in dishes and fixed for 30 min in 4% paraformaldehyde. The cells were permeabilized with 0.04% Triton X-100 for 10 min. The primary antibody, diluted in phosphate-buffered solution/5% bovine serum albumin, was applied for 1 h at 37 1C. Following phosphate-buffered solution washing steps, the appropriate Alexa Fluor 488-linked secondary antibody (Invitrogen) was applied for 30 min at room temperature. Controls were performed omitting the primary antibody and with the corresponding immunoglobulin G fraction as the primary antibody. Cells were counterstained with 4',6-diamidino-2-phenylindole, and images were taken on a fluorescence microscope.
In vivo tumorigenesis
Five-week-old male nude athymic BALB/c nu/nu mice were used to examine tumorigenicity. To evaluate the role of EphA2 in tumor formation, three groups of gastric cancer cell SGC-7901 ('blank', 'EphA2' and 'EphA2 Si') were propagated and inoculated subcutaneously into the flanks of nude mice (2 Â 10 6 cells in 0.2 ml volume). Tumor size was measured every 5 days. Tumor volumes were determined according to the following formula: A Â B 2 /2, where A is the largest diameter and B is the diameter perpendicular to A. After 30 days, the mice were killed and tumor mass were weighted. Immunohistochmesitry staining of EphA2, E-cadherin, Snail, N-cadherin and b-catenin was used on the mice tumor tissue slides. To assay EphA2's effect on tumor metastasis, the cells of the same three groups were injected into the tail vein of nude mice. After 30 days, necropsies were performed. Numbers of metastasis nodules in lung in individual mice were counted by two independent pathologists. The experiments were performed using five to six mice per group, and all EphA2 promotes EMT in gastric cancer J Huang et al animal procedures were performed in accordance with institutional guidelines.
Statistical analysis
The protein expression levels and clinicopathologic parameters were compared by w 2
